Ugrás a tartalomra
Merck
Összes fotó(1)

Fontos dokumentumok

MABE416

Sigma-Aldrich

Anti-Cisplatin DNA Adducts Antibody, clone ICR4

clone 1CR4, from rat

Szinonimák:

CP9/19, Cisplatin DNA modification

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

UNSPSC kód:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biológiai forrás

rat

Minőségi szint

antitest forma

purified antibody

antitest terméktípus

primary antibodies

klón

1CR4, monoclonal

faj reaktivitás

human

technika/technikák

ELISA: suitable
dot blot: suitable
immunohistochemistry: suitable

izotípus

IgG2aκ

kiszállítva

wet ice

célzott transzláció utáni módosítás

unmodified

Általános leírás

Cisplatin adducts are Guanine-Guanine (GG) DNA intrastrand cross links caused by the chemical compound Cisplatin. Cisplatin is used as a chemotherapy agent that contains platinum. The crosslinking of the DNA triggers apoptosis in the effected cell. Cisplatin is particularly effective in certain cancers such as testicular cancer. Unfortunately like most chemotherapy agents Cisplatin has many side effects and cancer cells typically will develop resistance to the drug after a period of time. Clone ICR4 was formerly known as clone CP9/19.

Egyediség

This antibody demonstrates specificity for cisplatin modified DNA.

Immunogen

Cisplatin modified native DNA.

Alkalmazás

Detect Cisplatin adducts using this rat monoclonal antibody, Anti-Cisplatin DNA Adducts Antibody, clone ICR4 validated for use in Dot Blot, ELISA & IHC.
ELISA Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in ELISA (Tilby, M. J., et al. (1991). Cancer Res. 51(1):123-129.; Kothandapani, A., et al. (2011). J Biol Chem. 286(16):14564-14574.; Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.; Strobeck, M. W., et al. (2000). Proc Natl Acad Sci USA. 97(14):7748-7753.; Kothandapani, A., et al. (2012). Exp Cell Res. 18(16):1973-1986.).

Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in Head and Neck Squamous Cell Carcinoma tissues. (Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.).
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Chromatin Biology

Minőség

Evaluated by Dot Blot in untreated and Cisplatin treated DNA from HeLa cell lysates.

Dot Blot Analysis: A 1:1,000 dilution of this antibody detected Cisplatin DNA Adducts in 1.0 and 0.5 µg of Cisplatin treated DNA from HeLa cell lysates.

Fizikai forma

Format: Purified
Protein G Purified
Purified rat monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Tárolás és stabilitás

Stable for 1 year at 2-8°C from date of receipt.

Egyéb megjegyzések

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Jogi nyilatkozat

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Nem találja a megfelelő terméket?  

Próbálja ki a Termékválasztó eszköz. eszközt

Tárolási osztály kódja

12 - Non Combustible Liquids

WGK

WGK 1

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable


Analitikai tanúsítványok (COA)

Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Az ügyfelek ezeket is megtekintették

Yonggen Zou et al.
Oncology letters, 15(1), 1097-1102 (2018-02-06)
As an important chemotherapeutic agent for the treatment of osteosarcoma, the effectiveness of cisplatin is considered to be due to its unique properties, which allow it to penetrate the cell membrane and form various DNA-platinum adducts, resulting in genetic alterations
Moon Soo Park et al.
Journal of the American Society of Nephrology : JASN, 13(4), 858-865 (2002-03-26)
Cisplatin, a commonly used chemotherapeutic agent, has a major limitation because of its nephrotoxicity. Recent studies have shown that cisplatin causes apoptotic cell death in renal tubule cells, but the underlying molecular mechanisms remain to be elucidated. In this study
Adrien Joseph et al.
Journal for immunotherapy of cancer, 9(6) (2021-06-25)
Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upregulation of
Jing Zhu et al.
Scientific reports, 6, 28861-28861 (2016-06-29)
Ethoxyquin was recently identified as a neuroprotective compound against toxic neuropathies and efficacy was demonstrated against paclitaxel-induced neurotoxicity in vivo. In this study we examined the efficacy of ethoxyquin in preventing neurotoxicity of cisplatin in rodent models of chemotherapy-induced peripheral
Stuart C Williamson et al.
Nature communications, 7, 13322-13322 (2016-11-09)
Small cell lung cancer (SCLC) is characterized by prevalent circulating tumour cells (CTCs), early metastasis and poor prognosis. We show that SCLC patients (37/38) have rare CTC subpopulations co-expressing vascular endothelial-cadherin (VE-cadherin) and cytokeratins consistent with vasculogenic mimicry (VM), a

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással